An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Toragen, Inc. Announces Appointment of Dr. Sandra Coufal, M.D. as CEO
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
Toragen Inc., based in San Diego, has announced the appointment of Dr. Sandra Coufal as its new CEO, bringing over 30 years of experience in medicine and biotechnology. Dr. Coufal's previous roles include co-founding Sibling Capital and serving on the Management Board of Tricida, Inc. (NASDAQ: TCDA). As the company prepares to submit an Investigational New Drug application to the FDA for its first clinical trial targeting cancers associated with human papillomavirus (HPV), Dr. Coufal aims to enhance drug selectivity and patient tolerance compared to traditional therapies.
Positive
Dr. Sandra Coufal's extensive experience in medicine and biotech expected to strengthen leadership.
Appointment comes ahead of Toragen's submission of an Investigational New Drug application to the FDA for first clinical trial.
Negative
None.
Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”)
SAN DIEGO--(BUSINESS WIRE)--
Toragen Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”), announced today that Dr. Sandra Coufal, M.D. will join Toragen as its new CEO. Dr. Coufal brings over 30 years of experience to Toragen as a physician and serial entrepreneur working with multiple successful companies in medicine, chemistry, biotechnology, material sciences, and digital technology.
Sandra Coufal, MD (Photo: Business Wire)
Most recently, Dr. Coufal co-founded and managed Sibling Capital Ventures and Sibling Capital, founded Relypsa’s and Ilypsa’s Scientific Advisory Boards, and co-founded and serves as Director on the Management Board of Tricida, Inc. (NASDAQ: TCDA). Since 2001, Dr. Coufal has also served as the Biomedical Advisor for the Genomics Institute of the Novartis Research Foundation. Previously, Dr. Coufal was Head of the Division of Internal Medicine at the Torrey Pines site of Scripps Clinic in La Jolla, CA, where she also sat on the Board of Scripps Green Hospital as the Representative-at-Large.
Dr. Coufal received her medical degree from the University of Texas Southwestern Medical School at Dallas. She also completed an internship and residency in Internal Medicine at the University of Texas Southwestern Medical School at Dallas under Chairman Dr. Daniel Foster. She received her Bachelor of Science undergraduate degree from the University of Notre Dame and was designated a Notre Dame Scholar.
Andrew Sharabi, MD, PhD, the founder and former CEO of Toragen and Assistant Professor of Radiation Medicine and Applied Sciences at UC San Diego Health, said, “Dr. Coufal is exceptionally qualified to lead Toragen at this important time as we prepare to submit an Investigational New Drug application to the Food and Drug Administration (FDA) for our first clinical trial in 2022. HPV associated cancers include Head and Neck Cancer, Cervical Cancer, and multiple other Genitourinary and Gastrointestinal Cancers. Toragen is developing drugs designed to inhibit HPV oncogenes, the root cause of malignant transformation in these cancers. It is the Company’s intent that our drugs will be more selective for malignant cells and better tolerated by patients than traditional cytotoxic and radiation cancer therapy. Toragen’s drugs under development interfere with the ability for the HPV virus to inhibit the immune system and could thus enhance the ability for the immune system to eradicate these cancers and potentially augment the activity of existing immunotherapies for cancer.”
Dr. Sandra Coufal has been appointed as the new CEO of Toragen Inc.
What is Dr. Sandra Coufal's professional background?
Dr. Coufal has over 30 years of experience in medicine and biotechnology, co-founding Sibling Capital Ventures and serving on the Board of Tricida, Inc.
What is Toragen's primary focus?
Toragen develops selective drugs targeting cancers caused by human papillomavirus (HPV).
What significant milestone is Toragen preparing for?
Toragen is preparing to submit an Investigational New Drug application to the FDA for its first clinical trial.
How does Toragen's drug approach differ from traditional therapies?
Toragen's drugs aim to inhibit HPV oncogenes selectively and improve patient tolerance compared to traditional cytotoxic and radiation therapies.
